Urine neutrophil gelatinase associated lipocalin as an early marker of acute kidney injury in hematopoietic stem cell transplantation patients

Figures & data

Figure 1. Serum creatinine (Cr) and urine neutrophil gelatinase-associated lipocalin (uNGAL) concentrations changes during study period in patients who developed acute kidney injury (AKI).

Table1. Patients’ demographic and clinical characteristics.

Characteristics	Study patients (n = 72)
Age (yr), mean (SD)	33 (11)
BMI (kg/m^2), mean (SD)	24.8 (4.2)
Female Sex, No. (%)	21 (29)
Diagnosis, No. (%)
AML	34 (47)
ALL	33 (46)
MDS	5 (7)
CR status, No. (%)
CR1	60 (83)
CR2	11 (15)
CR3	1 (2)
Baseline eGFR (mL/min), mean (SD)	120 (34)

Notes: AML, Acute myelogenous leukemia; ALL, Acute lymphoblastic leukemia; BMI, Body mass index; CR, Complete remission; eGFR, Estimated glomerular filtration rate; MDS, Myelodysplastic syndrome; SD, Standard deviation.

Table 2. Frequency and severity of acute kidney injury in study patients (n = 72).

AKI occurrence, No. (%)
RIFEL criteria	11 (15)
AKIN criteria	12 (17)
AKI stages, No
Risk/Injury (RIFEL criteria)	5/6
I/II (AKIN criteria)	6/6

Notes: AKI, Acute kidney injury; RIFLE, Risk–Injury–Failure–Loss–End-stage renal disease; AKIN, Acute Kidney Injury Network.

Figure 2. Natural Logarithm of urine neutrophil gelatinase-associated lipocalin (uNGAL) concentrations based on acute kidney injury (AKI) occurrence.

Table 3. Median (Range) of uNGAL concentrations and ratios to baseline in study patients.

	uNGAL (Median (Range))
	All patients	AKI occurrence
Day	(n = 72)	Yes (n = 12)	No (n = 60)
Baseline (day −6)	1.2 (40.9)	0.8 (13.8)	1.2 (40.9)
Day −3	1.2 (33.8)	0.3 (11.8)	1.3 (33.8)
Day +3	1.3 (18.9)	1.1 (5.9)	1.7 (18.9)
Day +9	2.2 (62.9)	5.1 (62.9)	1.3 (27.9)
Day +15	3.2 (27.9)	6.2 (27.7)	3.1 (19.9)
Day +3/ day −6 ratio	1.0 (15.5)	0.7 (6.8)	1.0 (15.4)
Day +9/ day −6 ratio	1.0 (54.9)	15.0 (54.0)	0.7 (49.9)
Day +15/ day −6 ratio	2.3 (99.9)	8.3 (43.0)	1.5 (99.9)

Notes: AKI, Acute kidney injury; uNGAL, urine neutrophil gelatinase-associated lipocalin.

Figure 3. Receiver-operating characteristic curve for day +9 to baseline urine neutrophil gelatinase-associated lipocalin (uNGAL) ratios.